Leerink Partners Maintains Market Perform on Alnylam Pharmaceuticals, Lowers Price Target to $351

Benzinga · 2d ago
Leerink Partners analyst Mani Foroohar maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and lowers the price target from $370 to $351.